Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Analysts broadly favor Immunic: Twelve brokerages give the stock an average “Buy” rating, including seven buys and three strong buys. Their average 12-month price target is $47.25, well above the recently reported $11.42 share price.
• Institutional ownership is significant: Hedge funds and other institutions own 51.82% of Immunic, with firms including Jane Street and Vanguard increasing their positions.
• Immunic reported a quarterly loss of $0.80 per share, beating the consensus estimate of a $1.16 loss. The clinical-stage biotech is developing oral therapies, led by its Phase 2 candidate vidofludimus calcium for inflammatory and autoimmune diseases.

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been given an average recommendation of "Buy" by the twelve brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $47.25.

A number of research firms have recently issued reports on IMUX. LADENBURG THALM/SH SH raised shares of Immunic to a "strong-buy" rating in a research note on Wednesday, July 29th. Roth Capital reiterated a "buy" rating on shares of Immunic in a report on Tuesday, September 1st. Wedbush reissued an "outperform" rating and issued a $45.00 target price on shares of Immunic in a research report on Thursday. B. Riley Financial decreased their price target on Immunic from $40.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 22nd. Finally, Wall Street Zen upgraded Immunic from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC increased its stake in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares during the period. Vanguard Group Inc. boosted its stake in shares of Immunic by 5.3% in the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company's stock valued at $3,832,000 after purchasing an additional 219,957 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Immunic in the third quarter valued at approximately $239,000. Two Sigma Investments LP acquired a new position in shares of Immunic in the third quarter valued at approximately $52,000. Finally, Virtu Financial LLC acquired a new position in shares of Immunic in the third quarter valued at approximately $99,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $11.42 on Monday. The business has a 50-day moving average price of $14.68 and a 200 day moving average price of $13.11. The company has a market capitalization of $155.77 million, a price-to-earnings ratio of -2.61 and a beta of 1.41. Immunic has a 12-month low of $5.06 and a 12-month high of $17.43.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.36. As a group, equities research analysts predict that Immunic will post -3.71 earnings per share for the current fiscal year.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.